Innovator’s Pitch Challenge

Medical Device

Tuesday, March 14
1:00 – 2:00pm ET

CorMatrix is a clinical stage regenerative medicine company focused on groundbreaking cardiovascular repair and regeneration technologies. With this round of funding, CorMatrix will complete its FDA clinical study and regulatory filing seeking to become the first company to receive US approval for a tricuspid valve; and the first to receive approval for a regenerative heart valve.  The company’s ongoing pivotal study for its regenerative valve targets a significant unmet clinical need as there is no FDA approved tricuspid valve in the marketplace.  The proceeds will also be used to enhance and confirm an already excellent reimbursement profile.  With these milestones, CorMatrix will lay the groundwork to launch its regenerative tricuspid valve to establish a new regenerative valvular replacement option for surgeons and patients – a true game changer in heart valve replacement – and prepare to disrupt the $10B structural heart market.

Contact Us:

John Engels